|
Don't Miss Out On The Hottest Newsletter!! Hear It Here First!! CBAI,OSIP,CDII,PMDP,MBCI,SNSR
(M2 PressWIRE Via Acquire Media NewsEdge) STOCK MARKETING INC PRESENTS : (OTCBB: CBAI) Cord Blood America, Inc., (NASDAQ: OSIP) OSI Pharmaceuticals, Inc., (NASDAQ: CDII) China Direct Industries, Inc., (PINKSHEETS: PMDP) Plateau Mineral Development, Inc., (OTCBB: MBCI) MabCure, Inc., (OTCBB: SNSR) Sanswire Corp.
www.StockMarketingInc.com
To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com
email us!! info@StockMarketingInc.com or call 1-866-583-8960
------------------------------------------------------------------------------------------------------------------------------------------------------------
(OTCBB: CBAI - Cord Blood America, Inc.)
LATEST NEWS!!
Cord Blood America Announces $1.35 Million Note Retired
Year Ends With Successful Debt Reduction -
LAS VEGAS, Jan 06, 2010 -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today said that it has retired a $1.35 million note which had been provided by JMJ Financial in May of 2009.
"We finished 2009 as we proceeded throughout the year, succeeding in a major effort to reduce debt and strengthen our balance sheet," said Matthew Schissler, CEO and co-founder, Cord Blood America. "The debt reduced, over $10.5 million, is the overwhelming majority we entered the year with and effectively all the debt available for retirement in 2009. We believe the minimal long term obligations left are immaterial in terms of standing in our way of future growth. This sets the table for 2010 to allow us to execute our three pillars of success: organic growth, acquisitions and diversification of our revenue stream." About Cord Blood America Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.
------------------------------------------------------------------------------------------------------------------------------------------------------------
(NASDAQ: OSIP - OSI Pharmaceuticals, Inc.)
LATEST NEWS!!
OSI Pharmaceuticals to Present at the 28th Annual JP Morgan Healthcare Conference on Tuesday, January 12, 2010
MELVILLE, N.Y., Jan 06, 2010 -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that OSI Management will present at the JP Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 12th at 3:00pm (Pacific Time) and will provide an overview on the Company's product portfolio and business developments.
The presentation will be webcast live and may be accessed by visiting OSI's website at www.osip.com. A replay of the webcast will also be available on the Company's website until January 29, 2010.
About OSI Pharmaceuticals OSI Pharmaceuticals is committed to "shaping medicine and changing lives" by discovering, developing and commercializing high-quality, novel and differentiated targeted medicines designed to extend life and improve the quality of life for patients with cancer and diabetes/obesity. For additional information about OSI, please visit http://www.osip.com.
------------------------------------------------------------------------------------------------------------------------------------------------------------
(NASDAQ: CDII - China Direct Industries, Inc.)
LATEST NEWS!!
China Direct Industries Provides Financial Outlook for Fiscal 2010 Ending September 30, 2010
Sees End Markets Improving and a Return to Profitability
DEERFIELD BEACH, FL, Jan 04, 2010 -- China Direct Industries, Inc. ("China Direct Industries") (NASDAQ: CDII), a U.S. owned holding company operating in China in two core business segments, pure magnesium production and distribution of basic materials, announced today its financial outlook for its fiscal 2010 year ending September 30, 2010.
As a result of improved visibility in the operations of its subsidiaries in China, coupled with continued price stabilization and improvement in demand in its magnesium segment, management has decided to reinitiate providing an annual financial outlook. Management sees improvement across all its business areas resulting in revenues for the full fiscal year of 2010 ranging between $130 and $150 million with net income ranging from $8 to $10 million. This guidance is predicated on management's belief that magnesium prices and demand will continue to gradually improve in fiscal 2010. Management also believes its consulting operations will improve significantly as global markets continue to strengthen for small to medium sized Chinese entities.
Commenting on its outlook, Dr. James Wang, Chairman and CEO of China Direct Industries, Inc. stated, "We have navigated the company through unprecedented difficulties and have worked diligently to remain in a solid financial position with operations capable of resuming growth when markets improve. We believe that that time is at hand in 2010 and we intend to work diligently on a return to profitability and a resumption of growth for all our businesses in China and the U.S. We are confident in our ability to deliver and optimistic that our end markets will continue to solidify and improve as we move throughout fiscal 2010." About China Direct Industries, Inc.
China Direct Industries, Inc. (NASDAQ: CDII), is a U.S. owned holding company operating in China in two core business segments, pure magnesium production and distribution and distribution of basic materials in China. China Direct Industries also provides advisory services to China based companies in competing in the global economy. Headquartered in Deerfield Beach, Florida, China Direct Industries operates 10 subsidiaries throughout China. This infrastructure creates a platform to expand business opportunities globally while effectively and efficiently accessing the U.S. capital markets. For more information about China Direct Industries, please visit http://www.cdii.net.
------------------------------------------------------------------------------------------------------------------------------------------------------------
(PINKSHEETS: PMDP - Plateau Mineral Development, Inc.)
LATEST NEWS!!
Plateau Mineral Development, Inc. Provides an Outline on Uses for Products of the Converter
WINSTON-SALEM, N.C., Jan 6, 2010 -- Plateau Mineral Development, Inc. (Pink Sheets:PMDP) announced today that the firm, in conjunction with Environmental Solutions, has issued a statement providing a pro-forma outline on the monetary benefits of solvent, which represents forty-six percent (46%) of the output. Other products of the converter will serve to greatly improve the profit margins of the tire converter.
Plateau's converter will generate solvent, carbon black and enough natural gas to operate in remote sites without additional power. The proposed unit is capable of processing approximately 6.25 lbs. of total product per minute.
At 6.25 lbs. per minute, 3,000 lbs. per 8-hour work day can be generated and transformed into approximately 7 gallons of solvent which sells for approximately $40/gallon, generating $7885.60 in revenue per day, which can lead to $157,712 per month. Additionally, solvent can be used to dissolve paraffin and to reduce the viscosity of heavy oils.
The market for carbon black includes the manufacturing of new tires as well as for producing batteries, making it an even more important commodity. Carbon black sells for approximately $0.46 per pound and is not included in the pro-forma above for the solvent.
Robert Matthews of Plateau Mineral Development, Inc. states, "We find that there's clearly a great profitability when it comes to the end products of the converter. Solvent, carbon black and natural gas are three items with high demand in the marketplace." About Plateau Mineral Development, Inc.: Plateau Mineral Development has been in existence for over five years.
------------------------------------------------------------------------------------------------------------------------------------------------------------
(OTCBB: MBCI - MabCure, Inc.)
LATEST NEWS!!
MabCure Launches Clinical Trial to Diagnose Ovarian Cancer
HASSELT, Belgium, Jan 06, 2010 -- MabCure, N.V. ("MabCure") a wholly-owned subsidiary of MabCure Inc. (OTCBB: MBCI) , a biotech company that has developed a series of highly specific monoclonal antibodies (MAbs) to combat various types of cancers, has signed a clinical research agreement with the Ramathibodi Hospital, Mahidol University in Bangkok, Thailand. The study aims to evaluate MabCure's panel of anti-ovarian MAbs in diagnosing the presence of ovarian cancer in patients suspected of having the disease.
Dr. Amnon Gonenne, MabCure's President and CEO commented, "We are very excited about the commencement of this study. We have been working hard to establish key partnerships with respectable research institutions and hospitals in Europe and the Far East, and this is no exception. We are looking forward to the results of the study and to moving MabCure forward towards having our diagnostic products on the market." "We know our diagnostic products have the potential to save many lives, and our mission is to get them to market as quickly as possible," Dr. Gonenne added.
Ovarian cancer is the most lethal of all gynecological cancers. According to estimates by the American Cancer Society (ACS), in 2009 alone 21,550 American women will have been diagnosed with ovarian cancer, and 14,600 American women are expected to die of this disease. The high mortality is mostly attributable to late diagnosis of the disease. According to the ACS, early detection of ovarian cancer, when the disease is still localized, can yield a five-year survival rate of 92% compared to 23% when the disease has already metastasized.
Recent advances in proteomics-based tests, which rely on measuring the relative abundance of normal proteins, help in estimating the likelihood of having ovarian cancer. However, by definition, these tests cannot provide a definitive diagnosis since they rely on statistical estimates and not on cancer-specific biomarkers. Furthermore, a new study by the National Cancer Institute [J. Natl Cancer Inst. 2010, 102:1-3, 26-38] reports that the use of such normal proteins for diagnosis of ovarian cancer may have limited practical usefulness for early intervention, since these proteins become substantially elevated only in the last year before clinical diagnosis. It is important to note that over 80% of ovarian cancer patients are clinically diagnosed with highly advanced disease (stages III and IV). Therefore, there is clearly an urgent need for the development of a definitive method for the early detection of ovarian cancer which relies on cancer-specific markers. The objective of MabCure's clinical studies is to apply its highly specific antibodies for the definitive diagnosis of ovarian cancer with the ultimate goal of early diagnosis when the disease is highly curable.
"MabCure's proprietary platform technology has allowed us to develop a number of cancer-specific MAbs that could be invaluable for the diagnosis of several types of lethal cancers, and we are looking forward to exploring their utility in the clinical setting as well," said Dr. Gonenne.
About MabCure MabCure is a biotechnology company whose vision is to change the perception of cancer as being a largely incurable disease. MabCure owns proprietary technology for the creation of unique and highly specific monoclonal antibodies (MAbs) which will be developed as diagnostic tools, imaging agents and drugs to treat lethal cancers. MabCure's initial goal is to develop its novel MAbs as diagnostic tools for the detection of ovarian and prostate cancers at an early stage, when these diseases are still localized and highly curable. For further information visit MabCure's website at http://www.mabcure.com.
------------------------------------------------------------------------------------------------------------------------------------------------------------
(OTCBB: SNSR - Sanswire Corp.)
LATEST NEWS!!
Sanswire Delivers Letter to Shareholders
Letter Provides Review of 2009 Achievements and Announces Goals for 2010
FORT LAUDERDALE, FL, Jan 06, 2010 -- Sanswire (OTCBB: SNSR) Dear Shareholders, For Sanswire, 2009 was a year of great progress and achievement. In 2010, we intend to build on the solid foundation we established, and with the arrival of the New Year, management believes this is an appropriate time to review our accomplishments and to set out the milestones for 2010.
On the product side, the major news was the design and construction of the STS-111, an airship that was developed in response to demands from partners seeking immediate solutions to operational challenges. In 2009, Sanswire: -- Entered into partnership with Global Telesat Corp. and raised the funds needed to commence construction of the STS-111 -- Executed an agreement with a top 10 US defense contractor to handle the systems integration phase of development and overall operations of the STS- 111 in the field -- Conducted a private demonstration of the STS-111 in Stuttgart, Germany
With respect to our technology, we are quite proud of the program's progress. During 2009, we: -- Conducted multiple flights to test various Sanswire-TAO platforms, including flight testing of our proprietary fuel gas propulsion system -- Designed and developed an automatic trim system (ATS) utilized to improve the airship's flight characteristics during flight -- Furthered the development of our in-house designed Autonomous Flight Control System -- Designed and demonstrated our 4-segment STS-111 platform and commenced construction of the commercial platform, a 5-segment version of the STS-111 airship
On the corporate side, we engaged an independent Board of Directors and stregnthened our senior management team resulting in bringing our public filings up to date. We are now listed on the Bulletin Board, and have more than doubled our market capitalization in 2009. In addition, we have engaged with outside accounting and communications experts to aid in growing Sanswire: -- We engaged a top accounting firm, NYC-based Rosen Seymour Shapss Martin &Company LLP -- We hired The Investor Relations Group, an award-winning investor relations and public relations firm with experience in security issues.
Thanks to IRG's efforts, we have received radio and tv coverage, and were featured in various industry leading professional publications, such as IEEE Spectrum, Aviation Week, and the Smithsonian's Air & Space Magazine
Looking ahead, our 2010 goals are ambitious but achievable as we plan to add more talent to our executive team and Board of Directors. As for our products, we anticipate 2010 will be a watershed year: -- We expect to complete the construction of the commercial 5-segment STS- 111, the industry's first multi-day endurance UAV, and begin long-endurance high-altitude testing in Germany -- We plan to unveil the commercial STS-111 airship to the US public at an event to be held at the Sanford International Airport in Orlando, FL, during the second quarter of this year -- After that event, we will ship the commercial STS-111 to our partner for systems integration and operational training -- In collaboration with our systems integration and operations partner, we plan to conduct a series of demonstrations for potential customers -- We will continue the effort to locate a manufacturing facility in the United States and to increase lobbying efforts to attain assistance from Federal, State and Local governments -- We plan to expand our commercial business partnerships as industry applications of the commercial STS-111 platform become more widely known -- We plan to work closely with our current alliances in pursuing contracts for the commercial STS-111 -- We expect to begin construction of the STS-230 and continue the development of the company's high altitude program and carry out our plans to produce a commercial High Altitude Long Endurance (HALE) platform
This summarizes Sanswire's achievements over the past 12 months and outlines our vision for 2010. 2009 was a very eventful year, and it would not have been possible without the hard work of our staff, the expertise of our engineering team, and above all, the support of our shareholders.
Sincerely, The Executive Management Team and Board of Directors Sanswire Corp.
About Sanswire Corp.
Sanswire Corp. (OTCBB: SNSR) is a developer of integrated aerospace communications products and services. The company specializes in the design and construction of autonomous, lighter-than-air UAVs (Unmanned Aerial Vehicles) capable of carrying payloads that provide persistent security solutions at low, mid, and high altitudes. Sanswire's airships and auxiliary products are designed for use by commercial and government-related entities that require real-time intelligence, surveillance, and reconnaissance support for homeland defense, maritime, and border missions. The company's long-term objective is to develop and deliver state-of-the-art airship technology that provides surveillance sensor suites and other advanced wireless broadband capabilities to the broader commercial markets.
------------------------------------------------------------------------------------------------------------------------------------------------------------
About StockMarketingInc.com
StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.
((Comments on this story may be sent to info@m2.com))
(c) 2010 M2 COMMUNICATIONS
[ Back To greentechnologyworld.com's Homepage ]
|
